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Background and Aim. EGFR is commonly expressed in cancers of the head and neck (H and N), and anti-EGFR agents have
demonstrated improvements in outcomes (TTP and OS). The aim of this study was to determine EGFR gene status in H and N
cancer patients treated with geﬁtinib and to correlate mutational status with clinico-pathological data and response. Patients and
Methods. Patients with histologically conﬁrmed H and N cancer having failed prior treatment for advanced disease entered this
compassionate-use-program. Nineteen patients received geﬁtinib. EGFR expression was assessed by IHC, gene copy number by
FISH,andmutationanalysiswasconductedforEGFR(18-21),KRAS,BRAF (V600E),andHER-2exon20.AnadditionalTKInaive
cohort of 73 patients was also screened. Results. Mutations were detected in 6/19 patients (3× EGFR,1 × KRAS, and 2× HER2-
exon 20). There were no signiﬁcant diﬀerences in TTP or OS for patients with somatic EGFR mutations. No BRAF mutations
were detected. Conclusions. The incidence of EGFR mutations in H and N cancer in this study was 5.3%. No statistically relevant
correlations between mutation or gene gain and response or survival were observed. Due to the limited number of patients and
low incidence of genetic aberrations in the genes analyzed, additional studies are warranted.
1.Introduction
Cancer of the head and neck (H and N) is the ﬁfth most
common cancer in the United States, and despite signiﬁcant
progress in therapeutic modalities, almost half of patients




while new agents are being studied in platinum-refractory
metastatic disease.
The epidermal growth factor receptor (EGFR) along
with its ligands epidermal growth factor (EGF) and trans-
forming growth factor alpha (TGF-α)a r ei m p o r t a n ti n
m a n ya s p e c t so fc e l ls u r v i v a l ,d i ﬀerentiation, proliferation,
and invasion [3–5]. EGFR is almost universally expressed
in H and N cancers, and high levels of expression have
been correlated with poor outcome [6, 7]. Studies have
shown that blockade of EGFR signaling using antibody-
basedapproaches(cetuximab)canoﬀerimprovedoutcomes.
Recent randomized studies have demonstrated that the
combination of radiation with the anti-EGFR monoclonal2 Journal of Oncology
antibody cetuximab results in improvements of response
and overall survival over radiation alone in patients with
locallyadvancedHandNcancer[8].CombinationsofEGFR
inhibition with chemotherapy have also been studied with
promising results in the metastatic and recurrent settings [9,
10]. Although other EGFR inhibitors, such as small tyrosine
kinase inhibitors (TKIs; geﬁtinib and erlotinib) are available
forthetreatmentofothertumortypes;onlymodestresponse
rates of up to 11% as monotherapy have been obtained in
Ha n dNc a n c e r s[ 11, 12]. Considering that the oral TKI
erlotinib is licensed for second line NSCLC, and the TKI
geﬁtinib has recently been approved for ﬁrst line advanced
NSCLC carrying somatic EGFR mutations, a new level of
clinical interpretation may be necessary in this apparently
EGFR sensitive disease.
Geﬁtinib is an orally active and selective inhibitor of the
EGFR tyrosine kinase, which has principally been studied in
NSCLC. Clinical responses to geﬁtinib diﬀer among NSCLC
patients, and several studies have aimed at identifying
prognostic and/or predictive markers of response to these
agents. Clinical studies indicated that EGFR TKIs were
more eﬀective in women, of Asian origin, individuals with
adenocarcinoma, and never smokers [13, 14]. The impact of
EGFR expression levels on drug sensitivity is still an open
issue, since preclinical and clinical data show no obvious
correlationbetweenEGFRimmunohistochemicalexpression
and response although no thorough analysis has been
performed. EGFR gene copy number on the other hand has
been shown to be associated with improved response rates
and survival outcomes to TKI treatment compared to WT
patients, albeit in NSCLC [15, 16]. However, the deﬁning
molecular event appears to be the presence of activating
sensitizing mutations in EGFR [17–19]. These are virtually
exclusive to NSCLC but have been reported in numerous
other cancers [20]. Patients harboring such mutations have
a much higher response rate that is translated into improved
survival times compared to WT patients treated with EGFR
TKIs, at least in NSCLC [20, 21, unpublished observations:
S. Murray et al.]. The molecular signatures of NSCLC have
also highlighted that the presence of somatic mutations in
KRAS, occurring mutually exclusively to EGFR mutations,
earmarks tumors that are essentially resistant to TKIs [22].
Similar molecular events are being unearthed in colorectal
cancers with respect to treatment outcomes with the anti-
EGFR monoclonal antibodies cetuximab and panitumumab.
Here,mutationsinkeysignalingmoleculesKRAS[22],BRAF
[23], PIK3CA [24], and loss of expression of PTEN [25]h a v e
been correlated with a lack of response [26].
Many recent studies have consolidated our understand-
ing on the functional blockade of EGFR with various agents.
Investigations by numerous groups have now broadened
the scope of TKIs by the discovery of similar somatic




Although the response rates of H and N cancer to geﬁ-
tinib are similar to those seen in NSCLC, as yet there appear
to be no clinicopathological predictors so far identiﬁed for
the responsive cases. From limited literature studies in H and
N cancer, there are suggestions that EGFR mutations similar
to those in NSCLC exist, while there are other reports that
have failed to detect mutations [27–30]. However, recently
there have been reports of the presence of EGFR somatic
mutations in H and N cancers, albeit at a low incidence
(1–14%) [31–37]. Unlike NSCLC where there are multiple
studies investigating the predictive nature of gene copy
number analysis to TKIs, the data in H and N cancer remains
scant and inconclusive [27, 38, 39].
Based on the above, we hypothesized that if somatic mu-
tations and gene copy gain of EGFR occur in H and N
cancer, then treatment with a TKI such as geﬁtinib could
be a potentially beneﬁcial treatment option for many of
these patients. The objective of this study was to determine
whether the molecular mechanisms seen in NSCLC regard-
ing EGFR mutations and gene copy number and correlation
with TKI response extend to H and N cancer. Furthermore,
we extended this analysis to examine the incidence of
additional molecular events that have been proposed as
candidate biomarkers for response to anti-EGFR agents in
NSCLC and colorectal cancer.
2.MaterialsandMethods
2.1. Patients. Patients with histologically conﬁrmed H and
N cancer, who had failed prior treatment for advanced
or metastatic disease and were not amenable to further
chemotherapy or chemotherapy-na¨ ıve patients due to con-
traindication, were eligible for the study. Eligibility criteria
included an ECOG PS of 0–2, estimated life expectancy
of at least 3 months, adequate bone marrow, and hepatic
and renal function, indicated by an absolute neutrophil
count of ≥1,500/μl, platelets ≥75,000/μl, total bilirubin
≤2× the upper limit of normal; serum AST or ALT levels
≤3× the upper limit of normal; serum creatinine ≤2mg/dl;
serum albumin ≥2.5g/dl. Previous chemotherapy and/or
radiotherapy were allowed. All histological subtypes were
allowed. Patients with a history of serious cardiac disease,
other serious medical illness, or inability to comply with the
treatment plan and followup visits were excluded from the
study.
An additional cohort of 37 patients, previously reported
[40], were also included in this analysis for comparative
purposes.
A third cohort of anti-EGFR naive patients was also
included to aid in the study of the prognostic signiﬁcance
of the biomarkers analysed. These patients were randomly
selected from the School of Medicine, University of Thessa-
loniki, with the only entry criteria being adequate biological
materialaccessandpatient’sinformedconsentforbiomarker
analysis.
All patients signed informed consent as a requirement
for study inclusion. They similarly signed consent for the
use of biological materials for research purposes. The study
was conducted according to the Declaration of Helsinki
and the guidelines for Good Clinical Practice. The Local
Ethics Committees approved the study and the collection of
biological material.Journal of Oncology 3
2.2. TKI Treatment. Patients received geﬁtinib at a dose of
250mg per day orally. Geﬁtinib was supplied free of charge
by AstraZeneca as part of a compassionate use program.
Treatment was administered daily with a treatment cycle
constituting 28 days. Treatment was discontinued for up to
7 days for grade 3 or 4 toxicity, until resolution of toxicity
to ≤1. For non-resolving toxicities of more than 15 days,
patients were taken oﬀ study. Treatment was continued
until disease progression, serious adverse toxicity, at the
direction of the treating physician, or following patient
withdrawal. Patients were eligible for response evaluation
after completion of at least 2 months of treatment. All
patients have been routinely followedup at 6 monthly
intervalsfromtheirlasttreatment(dataonﬁle,HeCOGData
Oﬃce). Complete clinical data including smoking history,
clinical stage, pathological diagnosis, and response data for
all patients was available.
2.3. Determination of EGFR Expression. Paraﬃn blocks
of tumor were collected retrospectively, and peripheral
blood samples were collected during treatment or followup.
Immunohistochemical detection of EGFR was performed as
previously described [41] to semiquantify EGFR expression
levels. Tumor tissue sections showing 2+ or 3+ were consid-
ered as positive.
Assessment of EGFR gene copy number was conducted
by FISH and scored as previously described [40, 41].
2.4. Mutation Analyses. Genomic DNA was extracted from
paraﬃn embedded tumors as previously described [42]. All
paraﬃn blocks were examined on H and E for histological
veriﬁcation according to WHO [43], tumors consisting of
>75% tumor cell content (% TCC) were considered as
eligible for DNA extraction and sequence analysis. For those
biopsies where the % TCC was inadequate, macrodissection
on 5μm sections was performed to increase the content to
>75%.
Mutational analysis for all genes was conducted as previ-
ously described [40].
Additional genes for which analysis was conducted
included KRAS mutation analysis of codons 12 and 13.
PCR was performed using the same conditions as for EGFR,
usingKRAS-speciﬁcprimersamplifyingExon2aspreviously
described [40]. BRAF exons 14 and 15 were analyzed as
previously described [40], and the 3  and 5  intron-exon
splice sites of MET exon 14 were also screened. The primer
sequences for all reactions are available upon request.
All studied exons were conﬁrmed as previously described
above for EGFR [40]. All PCR products were puriﬁed by
solid-phase reversible immobilization chemistry followed
by bidirectional dye-terminator ﬂuorescent sequencing.
Sequences were analyzed by BLAST and chromatograms by
manual review and compared to the following representative
gene accession numbers: EGFR, NM 005228, and/or the
EGFRgenesequenceaccessionnumber:AF288738;KRAS,gi:
14277199; HER2 exon 20, gi: 23462913; MET, gi: 212720875
(http://www.ncbi.nlm.nci/).
The EGFR exon 21 mutation L858R which represents
approximately 40% of all reported mutations in NSCLC [44]
was also analyzed by PCR-RFLP based on the presence of
a new Sau96I restriction site created by the mutation [40].
KRAS mutations of codons 12 and 13 were also analyzed by
PCR-RFLP based on modiﬁed versions of the protocols of
Boldrini et al. [45] and Kislitsin et al. [46]. MET exon 14 5 
and 3  intron-exon deletions ﬁrst reported in NSCLC [47]
were also analyzed by a mutant allele-speciﬁc PCR method,
which only ampliﬁes in the presence of the given deletions,
while BRAF V600E was also analyzed by PCR-RFLP based
on a modiﬁed version of Salvesen et al. [48].
2.5. Statistical Analysis. Endpoints included TTP (time to
progression) and survival in association with the candidate
biomarkers. Survival was deﬁned as the time from ﬁrst day
of treatment until death from any cause. TTP was computed
as the time from initiation of treatment until recurrence
of tumor or death from any cause. The Fisher’s exact test
was used for comparing groups of categorical data, while
for continuous data the Mann-Whitney test. P-values of
at least .05 were considered statistically signiﬁcant. Kaplan-
Meier curves and log-rank test were used for comparing time
to event distributions. All analyses were performed using
SPSS version 18, in the HeCOG data oﬃce.
3. Results
3.1.ClinicopathologicalCharateristicsofWholeCohort. Char-
acteristics of the 73 TKI naive patients are listed in Table 1.
A subcohort of these patients received the anti-EGFR
agent cetuximab, and details of these patients have been
previously presented [49]. In the TKI treatment group, a
total of 19 patients were enrolled into a compassionate-
use program between 7/2002 and 11/2005. Geﬁtinib-treated
patients were predominantly white males, median age 66
years, with median PS 1. The majority of patients had
a strong smoking history (1 unknown), and the majority
had received prior chemotherapy (79%). Four patients had
never received chemotherapy (i.e., treatment na¨ ıve) entering
the compassionate use study due to contraindication to
standard chemotherapy. Since this study was not designed to
determine the response rate, TTP, or survival to treatment
with geﬁtinib, it was not deemed necessary to analyze
untreated patients in this investigational/translational study.
The second cohort of untreated (TKI naive) patients had
similar patient and tumor characteristics.
3.2. TKI-Treated Cohort
3.2.1. Treatment Characteristics. Patients received a total of
98 cycles of treatment (median 4 cycles, range 1–16 cycles).
At the time of analysis, all patients had died. Reasons
for treatment discontinuation included progression (5/19),
death (1/19), and patient refusal (2/19).
3.2.2. Response, TTP, and Survival. A total of 4 (21.1%) of
patients achieved an overall objective response (CR + PR)4 Journal of Oncology
Table 1: Patient and tumor characteristics by group.
TKI treated Naive
Number % Number %
Total 19 100 73 100
Gender






SCC 18 94.7 69 94.5
Other 1 5.3 2 2.7
Unknown 2 2.7
Smoking status
Yes 18 94.7 64 87.7
No 8 11.0
Unknown 1 5.3 1 1.3
Alcohol
Yes 11 57.9 56 76.7
No 7 36.8 15 20.5
Unknown 1 5.3 2 2.7
and further 6 (31.6%) achieved disease stabilization. Inter-
estingly only one of the responding patients had gene
copy number gain; the 3 patients with EGFR mutations
demonstrated disease stabilization. There were 19 disease
progressions for a median TTP of 3.6 months (95% CI: 1.5–
5.6) and a total of 19 deaths for a median survival of 6.5
months (95% CI: 2.4–10.6).
3.2.3. Somatic Mutation Analysis. We performed mutational
analysis of exons 18, 19, 20, and 21 of biopsy material from
19 patients with H and N cancer treated with Geﬁtinib. In
this cohort, a total of 4 diﬀerent somatic mutations located
within the exons of the TK domain of EGFR were observed
in 3 patients. Mutational status of all mutations was con-
ﬁrmed using germline DNA extracted from peripheral blood
or from macrodissected normal tissue available from the
paraﬃn embedded biopsy. Two patients harbored delL747-
P753insS (one with associated gene ampliﬁcation), Figure 1,
and another patient harbored V843I with a secondary silent
R846R somatic mutation (also in the presence of EGFR gene
ampliﬁcation), Table 4 and Figure 2.
No patient was found to harbor the common exon 21
mutation L858R either on sequencing or by RFLP. KRAS
mutations were observed in 1 patient, occurring at codon
12. EGFR and KRAS mutations were mutually exclusive. No
patient was found to harbor a BRAF V600E point mutation,
nor was there any other mutations observed in exon 15 of
the BRAF gene. Similarly no analyzed patient was found
to harbor an inton-exon 14 deletion of the MET gene.
Two patients were found to have somatic mutations within
Table 2: Molecular characteristics per group.
TKI treated Naive
(N = 19) (N = 73)
N % N %
RAS
MUT 1 5.3
WT 18 94.7 73 100.0
EGFR
MUT 3 15.8 1 1.4
WT 16 84.2 56 76.7
Unknown 16 21.9
MET











1 22 . 7
23 15.8 8 11.0
31 0 52.6 22 30.1
NE 2 10.5 3 4.1
Unknown 38 52.1
EGFR (FISH)
Ampliﬁed 3 15.8 1 1.4
Nonampliﬁed 13 68.4 32 43.8
NE 3 15.8
Unknown 40 54.8
exon 20 of HER-2, one harboring two independent point
mutations, Table 5, Figure 2.
Somatic mutations were detected in 6/19 patients
(3×EGFR,1 ×KRAS,a n d2 ×HER2-exon 20). The incidence
of EGFR mutations in this population was 15.8% (3/19).
Patients with somatic EGFR Exon19 deletions and point
mutations in Exon21 had a longer TTP and survival
compared to patients without mutations (not statistically
signiﬁcant), as shown in Table 4. For patients without
mutations, TTP was 2.2m versus 7.7m for patients with
mutations (Log Rank P = .145), and survival was 4.6m
for patients without mutations versus 11.6m for mutation
carriers (Log Rank P = .125). Similarly no statistical
signiﬁcant diﬀerence was found with respect to any other
biomarker analyzed in this study.
Immunohistochemical analysis for EGFR expression
identiﬁed positive tumors in 76.5% (13/17) of cases. ThreeJournal of Oncology 5
Table 3: Survival according to molecular markers for TKI-treated cohort.
Survival Log rank P TTP Log rank P
EGFR
MUT 11.7 .131 8.5 .106
WT 5.1 2.7
HER2
MUT 2.7 .340 1.2 .100
WT 6.5 4.1
EGFR (IHC)
Negative 8.9 .700 1.2 .641
Positive 4.6 3.6
EGFR (FISH)
Negative 4.6 .271 3.1 .185
Positive 11.7 8.5
EGFR combination: (Mutation and/or Gene gain)
Negative 4.6 .125 2.2 .145
Positive 11.6 7.7
Table 4: Response correlations. Patients, tumor characteristics and
mutations by response for TKI treated cohort.
CR or PR (N = 4) SD or PD (N = 13)
N % N % P
Alcohol .999
No 2 50.0 5 41.7
Yes 2 50.0 7 58.3
RAS .235
MUT 1 25.0
WT 3 75.0 13 100.0
EGFR .541
MUT 3 23.1
WT 4 100.0 10 76.9
HER2 .999
MUT 1 7.7
WT 4 100.0 12 92.3
EGFR (IHC) .516
Negative 4 33.3
Positive 3 100.0 8 66.7
EGFR (FISH) .999
Negative 3 100.0 8 72.7
Positive 3 27.3
patients hadgeneampliﬁcation of EGFR(twowith concomi-
tant somatic mutations in EGFR), and one additional patient
h a dg e n ec o p yn u m b e rg a i n( a n e u p l o i d y ) ,T a b l e5. Although
EGFRcopygainwasnotassociatedwithaprolongedsurvival
(survival was 11.64m), when we combined patients with a
somaticEGFRmutation and/or genecopy number gain,they
performedbetter(butnotstatisticalsigniﬁcant)comparedto
the wild-type (WT) group, 4.6 to 11.6 months, for survival;
2.2 to 7.7 months for TTP (WT versus mutation/gene gain,
resp.).





Figure 1: EGFR Exon 19 deletions. M: molecular weight markers;
1, 3, 4: WT Exon 19 EGFR; 2: delL747-P753insS Exon 19 and EGFR
gene ampliﬁcation; 5: delL747-P753insS Exon 19 EGFR.
3.3. Naive Cohort. The TKI naive cohort consisted of addi-
tional 73 patients, Tables 1 and 2. Of these patients, 37 have
previously been analyzed for EGFR and KRAS mutational
status [49]. These patients were included to obtain more
accurate estimation of the frequency of gene alterations
present in H and N cancers. The overall incidence per
aberration analyzed is indicated in Table 3.
4. Discussion
We have analyzed three diﬀerently selected populations
of H and N cancer in order to further understand the
incidence and potential predictive ability of a subset of
speciﬁc anti-EGFR candidate biomarkers. Although the
representative population of TKI-treated patients was small,
the incidence of both EGFR somatic mutations and gene
gain/ampliﬁcation was relatively high (3 and 4, resp., (2
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Figure 2: Representative chromatograms of somatic mutations (sense 5 ) of (a): HER2 Exon 20 Q795R; (b): HER2 Exon 20 W825X (Stop);
(c): HER2 Exon 20 Y781C; (d) EGFR Exon 21, R836R, and V843I.
to more closely reﬂect their respective incidence in a more
balanced population.
With the inclusion of 92 patients, the overall incidence
of EGFR mutations indicates that at 4% (4/92) they are rare
among cases of Hand N cancerwithin the Greek population.
A number of other authors have reported on the presence of
EGFR kinase domain mutations in H and N cancers. These
have ranged from not being detected from a total of 221
patients [27–30], through to between 1 and 14% in other
studies (n = 15/425) [31–37]. These diﬀerences suggest
that such mutations are a rare event, but that ethnicity
or other cofactors may play a role. Indeed, diﬀerences in
incidence have been well characterized with respect to EGFR
mutations in NSCLC, wherein the incidence is twice that in
Asians compared to Whites [20]. Bearing in mind that the
TKI geﬁtinib has recently gained license approval for the
treatment of ﬁrst line NSCLC for patients harboring EGFR
mutations[50],thesearchforsimilarbiomarkersofresponse
to anti-EGFR agents has become a priority in virtually all
cancer types.
Head and neck cancers are not without their fair share
of responses to anti-EGFR therapies. There are a number of
studies that have reported similar response rates of H and
N cancer to TKIs as to the response rates observed with
single agent TKIs in unselected NSCLC [11, 12]. Further
to this is the clinical utilization of anti-EGFR monoclonal
antibodies including cetuximab in the treatment of H and
Nc a n c e r s[ 8]. Given such utility and with the knowledge
that none of the biomarkers analyzed herein were found to
correlate with outcomes in the FLEX [51]study,eachofthese
biomarkers will need to be more thoroughly investigated
in H and N cancer. We also investigated the incidence of
EGFR gene copy gain ﬁnding 5.3% (1/19) of such patients.
This matches previous data indicating that between 8 and
30% of esophageal cancers have EGFR gene gain [52, 53].
As with EGFR somatic mutations, there is currently little
evidence to speculate on the overall predictive nature of
these aberrations in H and N cancers receiving anti-EGFR-
based agents. There are of course some limitations to
interpretations being derived from this study, the major of
which is the small sample size respective to the TKI-treated
population. Although there were diﬀerences between the
EGFR mutation positive and negative groups, their numbers
were small and any diﬀerence could simply be attributable
to chance. The relatively low incidences of such mutations
in H and N cancer, as well as mutations in KRAS, BRAF,
and HER2, indicate the necessity for analysis of much larger
patient populations together with investigation of alternative
molecular pathways and mechanisms to identify predictive
or prognostic markers.
In the continued search for additional biomarkers that
may be predictive of response to anti-EGFR agents, we and
others [12] have extrapolated data from breast cancer [54],
colorectal cancer [22, 26], and NSCLC [20]i no r d e rt o
address additional candidate genes/biomarkers to receptor
tyrosine kinases in general. As indicated in our cohorts, no
somatic mutations were identiﬁed in BRAF or MET.O n l y
one other report has analyzed HER2 mutations, suggestingJournal of Oncology 7
Table 5: Characteristics of patients receiving Geﬁtinib.





















1 38 Y PD 1.25 8.85 WT WT WT WT Y781C ND 0
2 50 Y PR 2.20 5.70 WT WT WT WT WT ND ND
3 75 Y SD 5.31 6.46 WT WT WT WT WT WT 0
4 59 Y NE 2.66 2.66 WT WT WT WT Q795R WT 3
W825X
5 63 Y SD 12.13 12.13 WT delL747-
P753insS WT WT WT Amp ND
6 66 Y PD 2.07 2.43 WT WT WT WT WT WT 3
7 63 Y SD 7.74 9.54 WT delL747-
P753insS WT WT WT WT 0
8 72 Y SD 8.46 11.70 WT R836R WT WT WT Amp 3
V843I
9 62 Y SD 7.84 8.03 WT WT WT WT WT ND 3
1 0 7 2 Y P R3 . 1 1 3 . 1 1 W TW TW TW TW T W T 3
1 1 7 5 Y P D5 . 1 5 5 . 1 5 W TW TW TW TW T A m p 2
12 66 N PR 4.10 11.64 WT WT WT WT WT Gain 2
13 74 N PD 3.57 9.15 WT WT WT WT WT WT 3
14 61 N PD 1.64 3.74 WT WT WT WT WT WT 3
15 70 N CR 15.05 17.57 G12D WT WT WT WT WT 3
16 69 Y PD 0.82 10.75 WT WT WT WT WT WT 0
1 7 6 3 Y P D0 . 7 5 2 . 8 9 W TW TW TW TW T W T 3
1 8 7 2 Y N E4 . 5 9 4 . 5 9 W TW TW TW TW T W T 3
1 9 5 9 Y S D1 . 4 8 3 . 8 0 W TW TW TW TW T W T 2
Abbreviations: Y: Yes; N: No; IHC: immunohistochemistry; FISH: ﬂuorescent in situ hybridization; ND: not determined; gain: aneuploidy; CR: complete
response; PR: partial response; SD: stable disease; PR: progressive disease; NE: not evaluable.
that they may be a potential biomarker of EGFR-TKI
sensitivity [12]. Although our investigation did not expand
into the other 2 cohorts, the Erbitux-treated cohort previ-
ously investigated [49] was also analyzed for the presence
of PTEN loss. Both PTEN and PIK3CA remain potential
candidate biomarkers of response to anti-EGFR agents.
Further analyses should incorporate analysis of these two
molecular events, as preliminary data suggests that PIK3CA
mutations may be as common as 20% [55]a n dP T E N
expression may be of predictive/prognostic signiﬁcance [56].
The limited data that currently exists not only to anti-EGFR
agents but also to chemotherapy in general in H and N
cancers beckons further concerted eﬀorts into additional
molecular taxinometry in order to start to substratify patient
populations for treatment individualization.
In conclusion, from a relatively small cohort of TKI-
treated H and N cancers, there is little evidence of any
single biomarker or biomarker algorithm from the genes
investigated as capable of subclassifying H and N cancer
into two distinct responsive subgroups. Although diﬀerences
in survival endpoints did not reach statistical signiﬁcance
between these groups, there are many contributing factors
to small retrospective analyses, such as inappropriate patient
selection and/or reporter bias compounding the analysis.
Considering that there are (to date) no eﬀective biomarkers
in H and N cancer, additional studies are welcome in order
to identify and further clarify if any underlying mechanisms
of response or resistance to anti-EGFR agents exist in H and
Nc a n c e r .
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